Regeneron Pharmaceuticals delivered strong fourth-quarter and full-year financial performances. The company currently has 20 compounds under various stages of clinical development. It had debt of US$1.98b, up from none in one year. However, it does have US$3.59b in cash offsetting this, leading to net cash of US$1.61b.
